地塞米松EP杂质E
| 中文名称 | 地塞米松EP杂质E |
|---|---|
| 中文同义词 | 地塞米松EP杂质E;地塞米松杂质E(EP);16Α-甲基-9,11-脱氢泼尼松龙;地塞米松杂质杂质E;地塞米松磷酸钠杂质E;地塞米松磷酸钠杂质EP E;地塞米松磷酸钠杂质EP F;糠酸莫米松杂质22 |
| 英文名称 | Dexamethasone EP Impurity E |
| 英文同义词 | 17,21-dihydroxy-16alpha-methylpregna-1,4,9(11)-triene-3,20-dione;16α-Methyl-9,11-dehydro Prednisolone;Dexamethasone impurity E;Dexamethasone Impurity 5(Dexamethasone EP Impurity E);(16α)-17,21-Dihydroxy-16-Methylpregna-1,4,9(11)-triene-3,20-dione;17.alpha.,21-Dihydroxy-16.alpha.-methylpregna-1,4,9(11)-triene-3,20-dione;Dexamethasone Impurity L;(8S,10S,13S,14S,16R,17R)-17-hydroxy |
| CAS号 | 13209-41-1 |
| 分子式 | C22H28O4 |
| 分子量 | 356.46 |
| EINECS号 | 236-177-8 |
| 相关类别 | 杂质对照品;标准品;178-糠酸莫米松;地塞米松杂质;对照品-杂质对照品;杂质;医药研发中间体;Intermediates & Fine Chemicals;Pharmaceuticals;Steroids |
| Mol文件 | 13209-41-1.mol |
| 结构式 |  |
地塞米松EP杂质E 性质
| 熔点 | 228-231 °C(Solv: acetone (67-64-1); hexane (110-54-3)) |
|---|---|
| 沸点 | 548.3±50.0 °C(Predicted) |
| 密度 | 1.24±0.1 g/cm3(Predicted) |
| 储存条件 | Refrigerator |
| 溶解度 | 氯仿（微溶）、二恶烷（微溶）、乙酸乙酯（微溶） |
| 酸度系数(pKa) | 12.53±0.70(Predicted) |
| 形态 | 固体 |
| 颜色 | 淡黄色低 |
| InChIKey | ZYTXTXAMMDTYDQ-JBFVNPOPNA-N |
| SMILES | C1(=O)C=C2[C@](C)(C=C1)C1[C@]([H])([C@@]3([H])[C@@](CC=1)(C)[C@@](O)(C(=O)CO)[C@H](C)C3)CC2 |&1:4,9,11,13,17,23,r| |
Vamorolone (VBP15) inhibits TNFα-induced pro-inflammatory NF-κB signaling in C2C12 muscle cells at 1 nM or more. Vamorolone binds the glucocorticoid receptor (GR) and mineralocorticoid receptor (MR) with similar affinity.
Vamorolone (0.1, 1μM; 30 minutes) reduces production of IL1βand CCL5 inflammatory mediators in primary human macrophages.
Vamorolone is a first-in-class mineralocorticoid receptor (MR) antagonist/dissociative glucocorticoid receptor (GR) ligand.
Vamorolone (5-30 mg/kg; cherry syrup) shows a superior side effect profile compared to pharmacological glucocorticoids in
mdx
mice.
Vamorolone (30 mg/kg; orally; daily for 20 days) reduces CNS Inflammation in murine experimental autoimmune encephalomyelitis.
| Animal Model: | C57BL/6 mice (experimental autoimmune encephalomyelitis) |
| Dosage: | 30 mg/kg |
| Administration: | Orally; daily for 20 days (starting one day prior to MOG 33-55 peptide immunization and continuing) |
| Result: | Reduced CNS inflammation in murine experimental autoimmune encephalomyelitis. |
安全信息
| WGK Germany | WGK 3 |
|---|---|
| 存储类别 | 11 - 可燃固体 |
| 危险性类别 | 眼部刺激 类别2 皮肤致敏物 类别1 |